LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

LLY

1,004

-0.33%↓

JNJ

226.76

-1.74%↓

ABBV

210.42

-0.19%↓

UNH

393.66

-1.34%↓

AZN

181.62

-1.79%↓

Home・Aandelen Lijst・Amgen Inc

Amgen Inc

Gesloten

SectorGezondheidszorg

326.2 -3.03

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

325.13

Max

336.3

Belangrijke statistieken
By Trading Economics
Inkomsten	486M 1.8B
Verkoop	-1.3B 8.6B
K/W Sectorgemiddelde	22.936 51.415
EPS	5.15
Dividendrendement	2.91
Winstmarge	21.107
Werknemers	31,500
EBITDA	-2.3B 2.7B

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+8.47% upside

Dividenden
By Dow Jones
Dividendrendement Sectorgemiddelde	2.91% 2.34%
Volgende Winsten	4 aug 2026
Volgende dividenddatum	5 jun 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-5.4B 178B
Vorige openingsprijs	329.23
Vorige sluitingsprijs	326.2

Nieuwssentiment

By Acuity

32%

68%

81 / 345 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

270.44 / 276.44 Steun & Weerstand

Amgen Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

30 apr 2026, 20:16 UTC

Winsten

Amgen Posts Higher 1Q Profit, Revenue

6 apr 2026, 17:09 UTC

Belangrijke Marktbewegers

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

3 feb 2026, 21:49 UTC

Winsten

Amgen Logs Higher 4Q Revenue on Double-Digit Volume Boost

6 jan 2026, 15:14 UTC

Acquisities, Fusies, Overnames

Amgen Buys Dark Blue Therapeutics in Deal Worth Up to $840 Million

19 nov 2025, 21:55 UTC

Belangrijke Marktbewegers

Amgen Lung Cancer Drug Gets Full Approval From FDA

30 apr 2026, 20:01 UTC

Winsten

Amgen Sees FY26 EPS $15.62-EPS $17.10 >AMGN

30 apr 2026, 20:01 UTC

Winsten

Amgen 1Q Worldwide Prolia Sales $727M >AMGN

30 apr 2026, 20:01 UTC

Winsten

Amgen Sees FY26 Rev $37.1B-$38.5B >AMGN

30 apr 2026, 20:01 UTC

Winsten

Amgen Sees FY26 Adj EPS $21.70-Adj EPS $23.10 >AMGN

30 apr 2026, 20:01 UTC

Winsten

Amgen 1Q Adj EPS $5.15 >AMGN

30 apr 2026, 20:01 UTC

Winsten

Amgen 1Q Rev $8.62B >AMGN

30 apr 2026, 20:01 UTC

Winsten

Amgen 1Q Net $1.82B >AMGN

30 apr 2026, 20:01 UTC

Winsten

Amgen 1Q EPS $3.34 >AMGN

1 apr 2026, 20:07 UTC

Acquisities, Fusies, Overnames

Why 2026 Is Biotech's Comeback Year -- Barrons.com

4 feb 2026, 19:56 UTC

Marktinformatie

Amgen's Strong Core Growth Offsets Wait for Weightloss Drug -- Market Talk

3 feb 2026, 21:01 UTC

Winsten

Amgen 4Q Worldwide XGEVA Sales $447M >AMGN

3 feb 2026, 21:01 UTC

Winsten

Amgen 4Q Worldwide Enbrel Sales $532M >AMGN

3 feb 2026, 21:01 UTC

Winsten

Amgen 4Q Adj EPS $5.29 >AMGN

3 feb 2026, 21:01 UTC

Winsten

Amgen 4Q Net $1.33B >AMGN

3 feb 2026, 21:01 UTC

Winsten

Amgen 4Q Worldwide Prolia Sales $1.05B >AMGN

3 feb 2026, 21:01 UTC

Winsten

Amgen 4Q Rev $9.9B >AMGN

3 feb 2026, 21:01 UTC

Winsten

Amgen Sees FY Adj EPS $21.60-Adj EPS $23.00 >AMGN

3 feb 2026, 21:01 UTC

Winsten

Amgen 4Q Worldwide Neulasta Sales $132M >AMGN

3 feb 2026, 21:01 UTC

Winsten

Amgen Sees FY Rev $37B-$38.4B >AMGN

3 feb 2026, 21:01 UTC

Winsten

Amgen Sees FY EPS $15.45-EPS $16.94 >AMGN

3 feb 2026, 21:01 UTC

Winsten

Amgen 4Q EPS $2.45 >AMGN

28 jan 2026, 17:47 UTC

Winsten

Pharma Stocks Are Close to 'Breaking Out.' Earnings Could Set Them Free. -- Barrons.com

6 jan 2026, 14:01 UTC

Acquisities, Fusies, Overnames

Amgen: Deal Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid Leukemia >AMGN

6 jan 2026, 14:01 UTC

Acquisities, Fusies, Overnames

Amgen Acquires Dark Blue Therapeutics in Transaction Valued at Up to $840 Million >AMGN

6 jan 2026, 14:00 UTC

Acquisities, Fusies, Overnames

AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE >AMGN

Peer Vergelijking

Prijswijziging

Amgen Inc Prognose

Koersdoel

By TipRanks

8.47% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 364.7 USD 8.47%

Hoogste 427 USD

Laagste 300 USD

Gebaseerd op 24 Wall Street-analisten die 12-maands prijsdoelen bieden voor Amgen Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

24 ratings

Buy

Hold

Sell

Gebaseerd op 24 analisten die aandelenratings hebben gegeven aan Amgen Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

270.44 / 276.44Steun & Weerstand

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

81 / 345 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.